LDS/Medical Tests/S-100B Protein, Serum

S-100B Protein, Serum

The S-100B protein is a calcium-binding protein that belongs to the S100 family of proteins which are highly conserved and are predominantly expressed in astrocytes of the central nervous system (CNS). It is also expressed in adipocytes, melanocytes, chondrocytes, Schwann cells, dendritic cells, and arterial smooth muscle cells. S-100B plays roles in intracellular protein phosphorylation, cytoskeleton regulation, calcium homeostasis, and cell proliferation/differentiation.

In extracellular context, S-100B acts as damage-associated molecular pattern (DAMP) protein which binds to the receptors for advanced glycation end products (RAGE) and triggers pro-inflammatory response. In neurology, S100B has been established as a biomarker of CNS injury since it is rapidly released into the CSF following astrocyte activation or damage. As such, elevations in the level of CSF S100B can be observed in traumatic brain injury, and neurodegenerative disorders like Alzheimer’s, Parkinson’s, ALS, and multiple sclerosis.

Higher levels of S100B correlate with the extent of injury and poorer prognosis. S100B has also been correlated with ischemic stroke in terms of infarct size, neurological deterioration, and prognosis. In Parkinson’s disease, the level of S100B has been related with dopaminergic neuron loss. S100B can be easily measured by ELISA or electrochemiluminescence. Additionally, S100B and its associated pathways have been studied as a great therapeutic target of interest.

  • As an aid in the diagnosis and prognosis of traumatic brain injury
  • As an aid in the diagnosis and management of brain cancer
  • As an aid in the diagnosis and disease management in neurodegenerative and demyelinating diseases

Increased in:

  • Traumatic brain injury (elevations correlate with injury severity and outcomes)
  • Ischemic and hemorrhagic stroke
  • Alzheimer’s disease
  • Parkinson’s disease
  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis
  • Metastatic melanoma (due to expression in melanocytes)

Note: Elevations may occur in extracranial trauma, systemic inflammation, or after major surgery; interpretation must consider clinical context.

Age Range Reference Interval
19 years and older 0 – 96 ng/L
3 years to 19 years ≤ 160 ng/L
25 months to 3 years ≤ 170 ng/L
10 months to 25 months ≤ 230 ng/L
5 months to 10 months ≤ 350 ng/mL
0 days to 5 months ≤ 510 ng/mL

 

Enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence immunoassay (ECLIA).

CSF, serum (SST).

Stability

  • Ambient: 24 hrs
  • Refrigerated: 3-7 days
  • Frozen: 90 days
Tau/Theta proteins, neuron-specific enolase (NSE), ApoE genotyping, comprehensive metabolic panel, hepatic function panel, vitamin B12, folic acid, Lyme serology, CBC.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login